{"id":22275,"date":"2025-03-27T10:44:36","date_gmt":"2025-03-27T09:44:36","guid":{"rendered":"https:\/\/synektik.com.pl\/?p=22275"},"modified":"2025-03-27T13:57:24","modified_gmt":"2025-03-27T12:57:24","slug":"synektik-plans-to-divide","status":"publish","type":"post","link":"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/","title":{"rendered":"Synektik plans to divide. It is spinning off the cardiotracer research project into a new company which will also be listed on the WSE"},"content":{"rendered":"\n

Synektik, a provider of advanced solutions for medicine, including innovative medical devices and IT solutions, and the leading Polish producer of radiopharmaceuticals, intends to split into two independent companies. The listed firm plans to spin off the business connected with cardiotracer research into a new entity. This will open up new possibilities to raise financing for further clinical trials and future commercialization of this innovative radiopharmaceutical, with global sales potential. The rest of the operating activity will remain at Synektik, which after the split will be a company with higher profitability and significant dividend potential. <\/strong><\/h2>\n\n\n\n

As a result of the split, Synektik\u2019s shareholders will take up shares of the new company (proportionally to the shares they hold). Both companies will be listed on the Warsaw Stock Exchange. The management board intends to finalize the split within the first half of 2026.<\/strong><\/p>\n\n\n\n

\u201cSynektik currently conducts diverse operations,\u201d explained Cezary Kozanecki, founder and CEO of Synektik<\/strong>. \u201cOn one hand it is involved in sales and servicing of medical equipment, as well as production of radiopharmaceuticals, and these constitute a source of predictable, rising revenues and profits. On the other hand, the company is conducting costly research, primarily on a cardiotracer which has huge potential related to its future commercialization but at the current stage is not yet generating revenue. These two types of activity attract investors with a different profile and varying appetite for risk. Dividing these operations into independent companies will allow investors to make a separate and reliable assessment reflecting the potential of each company. I believe that, as a consequence, this will lead to increasing the value of both companies, while exploiting new possibilities for financing further growth, but <\/s>based however on different strategies tailored to their differing business models.\u201d<\/p>\n\n\n\n

New possibilities for financing and commercializing cardiotracer<\/strong><\/p>\n\n\n\n

As a result of the planned division, the portion of the R&D centre activity connected with the research into new pharmaceutical compounds, in particular research on a cardiotracer, i.e. an innovative radiopharmaceutical designed for testing myocardial perfusion and diagnosis of coronary artery disease, will be spun off into a new company (working name \u201cSyn2bio\u201d).<\/p>\n\n\n\n

The cardiotracer enables detection of myocardial perfusion disorders in patients with suspected or confirmed coronary artery disease. It also enables analysis of the patient\u2019s health and prognosis after suffering myocardial infarction and in ischemic heart disease, as well as assessment of the severity of atherosclerotic lesions in the coronary arteries. Synektik holds the exclusive rights to produce and sell this tracer throughout the world.  It is also subject to patent protection on key markets, including Europe and Japan.<\/p>\n\n\n\n

According to Cezary Kozanecki<\/strong>, \u201cThe cardiotracer is our flagship project, with global sales potential. We have successfully completed phase one and two of clinical trials, and are now at an advanced stage of phase three trials. The new entity is to continue the clinical trials and then handle commercialization of the cardiotracer. The main source of future revenues of Syn2bio will be partnering agreements, for example licences for production of the cardiotracer granted to third parties, in Western Europe and the United States among other places, or in-house production of this radiopharmaceutical by Syn2bio.\u201d<\/p>\n\n\n\n

In Synektik\u2019s view, the biggest potential connected with future commercialization of the cardiotracer lies in the United States, where some 7 million myocardial perfusion tests are performed each year. Today, most of these tests are performed using the SPECT method, but every year a larger and larger percentage of these tests are conducted using the new, more precise PET-CT method, which would also be used for the company\u2019s cardiotracer. The market with the second-largest potential is Europe.<\/p>\n\n\n\n

\u201cWe assume that while spinning off the cardiotracer project into a new company, we will furnish the new company with the appropriate resources to continue the clinical trials for a certain period after the split,\u201d said Cezary Kozanecki<\/strong>. \u201cThe new entity will also be able to seek funding from grants and R&D financing schemes earmarked for SMEs, which are not currently accessible to Synektik as a large enterprise. Alongside additional external financing, it will also be easier for Syn2bio, focused on development of the cardiotracer project and the search for new pharmaceutical compounds, to attract investors, including industry investors, who are interested in this business profile, accepting a different level of risk and expecting a higher potential rate of return in the future. This also opens up opportunities for a broader quest for new research projects and acceleration of their commercialization\u2014under more favourable terms than in the case of commercialization at an earlier stage under the existing model for financing such projects by Synektik.\u201d<\/p>\n\n\n\n

Synektik\u2014a mature, dividend-paying company<\/strong><\/p>\n\n\n\n

The other business conducted by Synektik will remain within the existing company. It will continue to handle such matters as distribution and servicing of innovative medical equipment (including the da Vinci robotic systems, as their sole distributor for Poland, Czechia, Slovakia, and the Baltic States), development of its own IT solutions, production and sale of radiopharmaceuticals, as well as R&D in the search for generics of existing radiopharmaceutical products which do not require long-term clinical trials.<\/p>\n\n\n\n

According to Dariusz Korecki, VP of Synektik<\/strong>, \u201cToday, Synektik is a mature, highly profitable company with the potential for further steady growth in sales and income. However, the results currently generated by Synektik are also burdened by the high costs of research on the cardiotracer, amounting to over PLN 20 million per year. Transferring this project to an independent entity will enable it to obtain other sources of financing, while allowing Synektik to strengthen its image as a company with higher profitability and predictable growth in dividend distributions.\u201d<\/p>\n\n\n\n

Two promising companies on the WSE<\/strong><\/p>\n\n\n\n

Following the split, both Synektik and Syn2bio will be listed on the Warsaw Stock Exchange. As part of the planned division, Synektik\u2019s shareholders will be allocated shares in the new company proportional to the shares they hold on the reference date. The shares will be allocated via a public offering of shares, which will entail the necessity for preparation of a prospectus by Syn2bio and approval of the prospectus by the Polish Financial Supervision Authority (KNF).<\/p>\n\n\n\n

According to Cezary Kozanecki<\/strong>, \u201cWe are at the beginning of the process aimed at dividing Synektik and listing the shares of the new company on the WSE. Assuming that the prospectus is confirmed by KNF, all corporate approvals are obtained as planned, and the proposed split wins the approval of Synektik\u2019s general meeting, it is our intention to finalize the division in the first half of 2026. We will report on all of the key stages in executing this plan on an ongoing basis, in accordance with the rules applicable to public companies.\u201d<\/p>\n\n\n\n

\n
Current report<\/a><\/div>\n<\/div>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Synektik, a provider of advanced solutions for medicine, including innovative medical devices and IT solutions, and the leading Polish producer of radiopharmaceuticals, intends to split into two independent companies. The listed firm plans to spin off the business connected with cardiotracer research into a new entity. This will open up new possibilities to raise financing […]<\/p>\n","protected":false},"author":7,"featured_media":14599,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[289,247,248,249],"tags":[],"class_list":["post-22275","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-innovations","category-investor-relations","category-news","category-press-releases"],"acf":[],"yoast_head":"\nSynektik plans to divide. It is spinning off the cardiotracer research project into a new company which will also be listed on the WSE - Synektik<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Synektik plans to divide. It is spinning off the cardiotracer research project into a new company which will also be listed on the WSE - Synektik\" \/>\n<meta property=\"og:description\" content=\"Synektik, a provider of advanced solutions for medicine, including innovative medical devices and IT solutions, and the leading Polish producer of radiopharmaceuticals, intends to split into two independent companies. The listed firm plans to spin off the business connected with cardiotracer research into a new entity. This will open up new possibilities to raise financing […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/\" \/>\n<meta property=\"og:site_name\" content=\"Synektik\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/Synektik\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-27T09:44:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-27T12:57:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/synektik.jcd.pl\/wp-content\/uploads\/2023\/10\/Synektik_farmacja_szpitalna.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1041\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"mkowalewska@synektik.com.pl\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@synektik1\" \/>\n<meta name=\"twitter:site\" content=\"@synektik1\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/\"},\"author\":{\"name\":\"mkowalewska@synektik.com.pl\",\"@id\":\"https:\/\/synektik.jcd.pl\/#\/schema\/person\/7b0818f36c4e1476e21c7d1408935628\"},\"headline\":\"Synektik plans to divide. It is spinning off the cardiotracer research project into a new company which will also be listed on the WSE\",\"datePublished\":\"2025-03-27T09:44:36+00:00\",\"dateModified\":\"2025-03-27T12:57:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/\"},\"wordCount\":1153,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/synektik.jcd.pl\/#organization\"},\"image\":{\"@id\":\"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/synektik.jcd.pl\/wp-content\/uploads\/2023\/10\/Synektik_farmacja_szpitalna.jpg\",\"articleSection\":[\"Innovations\",\"Investor relations\",\"News\",\"Press releases\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/\",\"url\":\"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/\",\"name\":\"Synektik plans to divide. It is spinning off the cardiotracer research project into a new company which will also be listed on the WSE - Synektik\",\"isPartOf\":{\"@id\":\"https:\/\/synektik.jcd.pl\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/synektik.jcd.pl\/wp-content\/uploads\/2023\/10\/Synektik_farmacja_szpitalna.jpg\",\"datePublished\":\"2025-03-27T09:44:36+00:00\",\"dateModified\":\"2025-03-27T12:57:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/#primaryimage\",\"url\":\"https:\/\/synektik.jcd.pl\/wp-content\/uploads\/2023\/10\/Synektik_farmacja_szpitalna.jpg\",\"contentUrl\":\"https:\/\/synektik.jcd.pl\/wp-content\/uploads\/2023\/10\/Synektik_farmacja_szpitalna.jpg\",\"width\":1041,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/synektik.jcd.pl\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Synektik plans to divide. It is spinning off the cardiotracer research project into a new company which will also be listed on the WSE\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/synektik.jcd.pl\/#website\",\"url\":\"https:\/\/synektik.jcd.pl\/\",\"name\":\"Synektik\",\"description\":\"Grupa Synektik jest wiod\u0105cym producentem zaawansowanych produkt\u00f3w radiofarmaceutycznych oraz rozwi\u0105za\u0144 informatycznych, dostawc\u0105 us\u0142ug serwisowo-pomiarowych oraz dystrybutorem innowacyjnych urz\u0105dze\u0144 medycznych, stosowanych w diagnostyce oraz terapii w dziedzinach radiologii, onkologii, kardiologii i neurologii.\",\"publisher\":{\"@id\":\"https:\/\/synektik.jcd.pl\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/synektik.jcd.pl\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/synektik.jcd.pl\/#organization\",\"name\":\"Synektik Group\",\"url\":\"https:\/\/synektik.jcd.pl\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/synektik.jcd.pl\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/synektik.com.pl\/wp-content\/uploads\/2024\/07\/synektik-logo.png\",\"contentUrl\":\"https:\/\/synektik.com.pl\/wp-content\/uploads\/2024\/07\/synektik-logo.png\",\"width\":675,\"height\":675,\"caption\":\"Synektik Group\"},\"image\":{\"@id\":\"https:\/\/synektik.jcd.pl\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Synektik\/\",\"https:\/\/x.com\/synektik1\",\"https:\/\/www.linkedin.com\/company\/synektik\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/synektik.jcd.pl\/#\/schema\/person\/7b0818f36c4e1476e21c7d1408935628\",\"name\":\"mkowalewska@synektik.com.pl\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/synektik.jcd.pl\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b917b3de54baf27157b46fa00a3c83a8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b917b3de54baf27157b46fa00a3c83a8?s=96&d=mm&r=g\",\"caption\":\"mkowalewska@synektik.com.pl\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Synektik plans to divide. It is spinning off the cardiotracer research project into a new company which will also be listed on the WSE - Synektik","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Synektik plans to divide. It is spinning off the cardiotracer research project into a new company which will also be listed on the WSE - Synektik","og_description":"Synektik, a provider of advanced solutions for medicine, including innovative medical devices and IT solutions, and the leading Polish producer of radiopharmaceuticals, intends to split into two independent companies. The listed firm plans to spin off the business connected with cardiotracer research into a new entity. This will open up new possibilities to raise financing […]","og_url":"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/","og_site_name":"Synektik","article_publisher":"https:\/\/www.facebook.com\/Synektik\/","article_published_time":"2025-03-27T09:44:36+00:00","article_modified_time":"2025-03-27T12:57:24+00:00","og_image":[{"width":1041,"height":800,"url":"https:\/\/synektik.jcd.pl\/wp-content\/uploads\/2023\/10\/Synektik_farmacja_szpitalna.jpg","type":"image\/jpeg"}],"author":"mkowalewska@synektik.com.pl","twitter_card":"summary_large_image","twitter_creator":"@synektik1","twitter_site":"@synektik1","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/#article","isPartOf":{"@id":"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/"},"author":{"name":"mkowalewska@synektik.com.pl","@id":"https:\/\/synektik.jcd.pl\/#\/schema\/person\/7b0818f36c4e1476e21c7d1408935628"},"headline":"Synektik plans to divide. It is spinning off the cardiotracer research project into a new company which will also be listed on the WSE","datePublished":"2025-03-27T09:44:36+00:00","dateModified":"2025-03-27T12:57:24+00:00","mainEntityOfPage":{"@id":"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/"},"wordCount":1153,"commentCount":0,"publisher":{"@id":"https:\/\/synektik.jcd.pl\/#organization"},"image":{"@id":"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/#primaryimage"},"thumbnailUrl":"https:\/\/synektik.jcd.pl\/wp-content\/uploads\/2023\/10\/Synektik_farmacja_szpitalna.jpg","articleSection":["Innovations","Investor relations","News","Press releases"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/","url":"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/","name":"Synektik plans to divide. It is spinning off the cardiotracer research project into a new company which will also be listed on the WSE - Synektik","isPartOf":{"@id":"https:\/\/synektik.jcd.pl\/#website"},"primaryImageOfPage":{"@id":"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/#primaryimage"},"image":{"@id":"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/#primaryimage"},"thumbnailUrl":"https:\/\/synektik.jcd.pl\/wp-content\/uploads\/2023\/10\/Synektik_farmacja_szpitalna.jpg","datePublished":"2025-03-27T09:44:36+00:00","dateModified":"2025-03-27T12:57:24+00:00","breadcrumb":{"@id":"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/#primaryimage","url":"https:\/\/synektik.jcd.pl\/wp-content\/uploads\/2023\/10\/Synektik_farmacja_szpitalna.jpg","contentUrl":"https:\/\/synektik.jcd.pl\/wp-content\/uploads\/2023\/10\/Synektik_farmacja_szpitalna.jpg","width":1041,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/synektik.jcd.pl\/en\/synektik-plans-to-divide\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/synektik.jcd.pl\/en\/"},{"@type":"ListItem","position":2,"name":"Synektik plans to divide. It is spinning off the cardiotracer research project into a new company which will also be listed on the WSE"}]},{"@type":"WebSite","@id":"https:\/\/synektik.jcd.pl\/#website","url":"https:\/\/synektik.jcd.pl\/","name":"Synektik","description":"Grupa Synektik jest wiod\u0105cym producentem zaawansowanych produkt\u00f3w radiofarmaceutycznych oraz rozwi\u0105za\u0144 informatycznych, dostawc\u0105 us\u0142ug serwisowo-pomiarowych oraz dystrybutorem innowacyjnych urz\u0105dze\u0144 medycznych, stosowanych w diagnostyce oraz terapii w dziedzinach radiologii, onkologii, kardiologii i neurologii.","publisher":{"@id":"https:\/\/synektik.jcd.pl\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/synektik.jcd.pl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/synektik.jcd.pl\/#organization","name":"Synektik Group","url":"https:\/\/synektik.jcd.pl\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/synektik.jcd.pl\/#\/schema\/logo\/image\/","url":"https:\/\/synektik.com.pl\/wp-content\/uploads\/2024\/07\/synektik-logo.png","contentUrl":"https:\/\/synektik.com.pl\/wp-content\/uploads\/2024\/07\/synektik-logo.png","width":675,"height":675,"caption":"Synektik Group"},"image":{"@id":"https:\/\/synektik.jcd.pl\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Synektik\/","https:\/\/x.com\/synektik1","https:\/\/www.linkedin.com\/company\/synektik\/"]},{"@type":"Person","@id":"https:\/\/synektik.jcd.pl\/#\/schema\/person\/7b0818f36c4e1476e21c7d1408935628","name":"mkowalewska@synektik.com.pl","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/synektik.jcd.pl\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b917b3de54baf27157b46fa00a3c83a8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b917b3de54baf27157b46fa00a3c83a8?s=96&d=mm&r=g","caption":"mkowalewska@synektik.com.pl"}}]}},"_links":{"self":[{"href":"https:\/\/synektik.jcd.pl\/en\/wp-json\/wp\/v2\/posts\/22275","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/synektik.jcd.pl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/synektik.jcd.pl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/synektik.jcd.pl\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/synektik.jcd.pl\/en\/wp-json\/wp\/v2\/comments?post=22275"}],"version-history":[{"count":2,"href":"https:\/\/synektik.jcd.pl\/en\/wp-json\/wp\/v2\/posts\/22275\/revisions"}],"predecessor-version":[{"id":22281,"href":"https:\/\/synektik.jcd.pl\/en\/wp-json\/wp\/v2\/posts\/22275\/revisions\/22281"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/synektik.jcd.pl\/en\/wp-json\/wp\/v2\/media\/14599"}],"wp:attachment":[{"href":"https:\/\/synektik.jcd.pl\/en\/wp-json\/wp\/v2\/media?parent=22275"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/synektik.jcd.pl\/en\/wp-json\/wp\/v2\/categories?post=22275"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/synektik.jcd.pl\/en\/wp-json\/wp\/v2\/tags?post=22275"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}